TABLE 9.

Evaluation of protection of different concentrations of formulation 2V of SPL7013 against genital herpes in guinea pigsd

TreatmentConcn (mg/ml)Fraction (%) of animals protected against:
DiseaseInfection
SPL7013 formulation 2V107/15 (47)5/15 (33)
SPL7013 formulation 2V2010/15 (67)9/15 (60)a
SPL7013 formulation 2V307/15 (47)7/15 (47)a
SPL7013 formulation 2V4011/15 (73)a10/15 (67)a
SPL7013 formulation 2V5012/15 (80)a11/15 (73)a
Placebo gel10/15 (67)8/15 (53)a
PBS4/15 (27)1/15 (7)
SPL7013 formulation 2V3016/18 (89)b,c15/18 (83)b,c
SPL7013 formulation 2V5017/18 (94)b,c16/18 (89)b,c
Placebo gel3/18 (17)2/18 (11)
PBS4/18 (22)3/18 (17)
  • a P < 0.05 versus PBS.

  • b P < 0.001 versus PBS.

  • c P < 0.001 versus placebo.

  • d Animals were treated 5 min prior to challenge.